Inspira Technologies Oxy B H N Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Inspira Technologies Oxy B H N Ltd (IINN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Inspira Technologies Oxy B H N Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 155M combined for tracked competitors (0.2% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-338.1% annualized vs trailing 12 months), vs decelerating (-40.8%) for its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Inspira Technologies Oxy B H N Ltd vs. its Competitors, Q4 2024
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Inspira Technologies Oxy B H N Ltd and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Inspira Technologies Oxy B H N Ltd | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Inspira Technologies Oxy B H N Ltd's competitor groups requires a Commercial License.
Inspira Technologies Oxy B H N Ltd's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Inspira Technologies Oxy B H N Ltd | - | - | - | Yes |
| Competitors combined (1) | ||||
| High-Confidence Competitors (6) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
IINN Stock Performance relative to its Competitors
IINN Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Neuronetics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Inspira Technologies Oxy B H N Ltd's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Inspira Technologies Oxy B H N Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Inspira Technologies Oxy B H N Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Inspira Technologies Oxy B H N Ltd | 47.69 | 0.29 |
| Neuronetics Inc | 186.84 | 154.59 |
| SUBTOTAL | 234.54 | 154.88 |
Sources: Inspira Technologies Oxy B H N Ltd's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Inspira Technologies Oxy B H N Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Inspira Technologies Oxy B H N Ltd's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Philips Healthcare | Named by the company | 85% |
| Boston Scientific Corporation | Named by the company | 85% |
| Masimo Corporation | Named by the company | 85% |
| Fisher & Paykel Healthcare Corporation Limited | Named by the company | 85% |
| ResMed Inc. | Named by the company | 85% |
| Chart Industries, Inc. | Named by the company | 85% |
| Medtronic plc | Named by the company | 85% |
| Becton, Dickinson and Company | Named by the company | 85% |
| Hamilton Medical AG | Named by the company | 85% |
| Smiths Medical Inc. | Named by the company | 85% |
| Drägerwerk AG & Co. KGaA | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Inspira Technologies Oxy B H N Ltd's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Inspira Technologies Oxy B H N Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Neuronetics Inc | Clinical Services Segment 63.04 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Inspira Technologies Oxy B H N Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Inspira Technologies Oxy B H N Ltd | 48 | - | - |
| Neuronetics Inc | 187 | 234,945 | -46,886 |
| PEERS TOTAL | 187 | 234,945 | -46,886 |
Inspira Technologies Oxy B H N Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 222 companies in Inspira Technologies Oxy B H N Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Inspira Technologies Oxy B H N Ltd ranks #0 of 222 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 587, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 145,832 | 13.38 % |
| 2 | Medtronic Plc | 113,372 | 10.40 % |
| 3 | Stryker Corp | 105,405 | 9.67 % |
| 4 | 3m Company | 88,542 | 8.12 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Dexcom Inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Alcon inc | 1,234 | 5.2% |
| 0 | Inspira Technologies Oxy B H N Ltd | 23 | 0.00 % |
Market cap and industry share for the rest of Inspira Technologies Oxy B H N Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-07-17.
Inspira Technologies Oxy B H N Ltd's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (288 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.69 % | 53.35 % (avg) | -52.7 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.82 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 35.64 % | 5.43 % (avg) | +30.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Inspira Technologies Oxy B H N Ltd's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | - | - | - |
| Operating Margin | - | - | - |
| Return on Invested Capital | -94.71 % | -124.88 % | -271.16 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Inspira Technologies Oxy B H N Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 587 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 35.64 % vs industry average 5.43 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Inspira Technologies Oxy B H N Ltd's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Inspira Technologies Oxy B H N Ltd's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Inspira Technologies Oxy B H N Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 577.5 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-338.1% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-40.8% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Inspira Technologies Oxy B H N Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Inspira Technologies Oxy B H N Ltd | 2.27 | 1.56 | - |
| Neuronetics Inc | 0.97 | 1.95 | 2.68 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Inspira Technologies Oxy B H N Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Inspira Technologies Oxy B H N Ltd | Q4 2024 | - | - |
| Neuronetics Inc | Q2 2026 | +10.2 % | - |
| PEERS TOTAL | +11.0 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Inspira Technologies Oxy B H N Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Inspira Technologies Oxy B H N Ltd | Q4 2024 | +5,820.0 % | -37.2 % |
| Neuronetics Inc | Q2 2026 | +1.7 % | +65.5 % |
Inspira Technologies Oxy B H N Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Inspira Technologies Oxy B H N Ltd | - | - | - |
| Neuronetics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Inspira Technologies Oxy B H N Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Inspira Technologies Oxy B H N Ltd | - | 165.03 |
| Neuronetics Inc | - | 1.21 |
| PEERS AVERAGE | - | 1.51 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.